NCT06708455: An ongoing trial by Rapa Therapeutics LLC
This trial is ongoing. It must report results 3 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06708455 |
|---|---|
| Title | Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 15, 2025 |
| Completion date | March 31, 2028 |
| Required reporting date | March 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Feb. 27, 2026 |
| Days late | None |